Molecular requirements for L-type Ca2+ channel blockade by testosterone

Area of Science:

• Cardiovascular Physiology
• Molecular Pharmacology

Background:

• Testosterone is known to have beneficial vascular effects, including vasodilation, which can alleviate symptoms of myocardial ischemia and angina.
• Existing in vitro studies have not elucidated a clear mechanism for testosterone's vasodilatory action.

Purpose of the Study:

• To investigate the molecular mechanism by which testosterone exerts its beneficial vascular effects.
• To determine if testosterone directly interacts with L-type calcium channels (Ca(v)1.2).

Main Methods:

• Whole-cell patch-clamp recordings were used to measure current flow through recombinant human L-type Ca2+ channel alpha(1C) subunits (Ca(v)1.2).
• The effect of testosterone and its metabolites/related hormones on Ca(v)1.2 channel activity was assessed.
• Site-directed mutagenesis (T1007Y) was employed to identify key residues for testosterone binding.

Main Results:

• Testosterone inhibited Ca(v)1.2 channel currents in a concentration-dependent manner within the physiological range (IC50 = 34 nM).
• This inhibitory effect was specific to testosterone and not observed with dihydrotestosterone (DHT), progesterone, or estradiol.
• A specific mutation (T1007Y) in the Ca(v)1.2 channel abolished sensitivity to both nifedipine and testosterone, indicating a shared binding site or mechanism.

Conclusions:

• Testosterone acts as an endogenous antagonist of vascular L-type Ca2+ channels.
• This study identifies the molecular basis for testosterone's interaction with Ca(v)1.2 channels.
• Findings support testosterone's role in cardiovascular health and suggest potential therapeutic applications as a calcium channel antagonist.